Health Sciences Acquisiti... (HSAQ)
Health Sciences Acquisitions 2 Statistics
Share Statistics
Health Sciences Acquisitions 2 has - shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | - |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 49 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -68.59 and the forward PE ratio is null. Health Sciences Acquisitions 2's PEG ratio is -0.09.
| PE Ratio | -68.59 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -23.61 |
| P/FCF Ratio | -103.8 |
| PEG Ratio | -0.09 |
Enterprise Valuation
Health Sciences Acquisitions 2 has an Enterprise Value (EV) of 163.75M.
| EV / Sales | 0 |
| EV / EBITDA | -59.87 |
| EV / EBIT | -103.69 |
| EV / FCF | -103.69 |
Financial Position
The company has a current ratio of 0.17, with a Debt / Equity ratio of 0.
| Current Ratio | 0.17 |
| Quick Ratio | 0.17 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 8.92 |
Financial Efficiency
Return on Equity is 34.41% and Return on Invested Capital is 38.76%.
| Return on Equity | 34.41% |
| Return on Assets | -3.51% |
| Return on Invested Capital | 38.76% |
| Revenue Per Employee | $- |
| Profits Per Employee | $- |
| Employee Count | undefined |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -345.14K |
| Effective Tax Rate | 12.62% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 0, so Health Sciences Acquisitions 2's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 10.07 |
| 200-Day Moving Average | 9.96 |
| Relative Strength Index (RSI) | 96.86 |
| Average Volume (20 Days) | 71.38K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -3.08M |
| Net Income | -2.39M |
| EBITDA | -2.74M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.15 |
Balance Sheet
The company has 175.16K in cash and 0 in debt, giving a net cash position of 175.16K.
| Cash & Cash Equivalents | 175.16K |
| Total Debt | 0 |
| Net Cash | 175.16K |
| Retained Earnings | -6.95M |
| Total Assets | 116.36M |
| Working Capital | 88.72M |
Cash Flow
In the last 12 months, operating cash flow was -1.58M and capital expenditures 0, giving a free cash flow of -1.58M.
| Operating Cash Flow | -1.58M |
| Capital Expenditures | 0 |
| Free Cash Flow | -1.58M |
| FCF Per Share | -0.1 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HSAQ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.46% |
| FCF Yield | -0.96% |
Analyst Forecast
Currently there are no analyst rating for HSAQ.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -0.54 |
| Piotroski F-Score | 4 |